TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17873679

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 15901634

Group type: EXPERIMENTAL
Intervention: leflunomide 20 mg daily (n=30)
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo (n=15)
Number of subjects: 45
Study: 11842297

Group type: COMPARATOR
Intervention: SIT-birch + placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: SIT-birch + anti-IgE
Number of subjects: 221

Group type: COMPARATOR
Intervention: SIT-grass + placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: SIT-grass + anti-IgE
Number of subjects: 221
Study: 9473540

Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/8-2 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/32 mg or more
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/4 mg or less
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/8-1/4 mg
Number of subjects: 48
Study: 7722961

Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Initial treatment with insulin
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study: 2500138

Group type: EXPERIMENTAL
Intervention: Carbamazepine (n = 43)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sodium valproate (n = 46)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 138
Study: 29287817

Group type: EXPERIMENTAL
Intervention: Growing Rod (GR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Magnetically Controlled Growing Rod (MCGR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aluminum (across all groups)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Boron (across all groups)
Number of subjects: 52
Study: 27940687

Group type: EXPERIMENTAL
Intervention: Initial Fio2 of 0.3 (Lowox group)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Initial Fio2 of 0.6 to 0.65 (Hiox group)
Number of subjects: 253
Study: 25238659

Group type: EXPERIMENTAL
Intervention: Group A (leuprolide acetate 1 mg s.c. injection 3 days after ET)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group B (two sequential doses of leuprolide acetate 1 mg s.c. injections 3 and 6 days after ET)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (routine luteal phase support only)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group A and B (leuprolide acetate)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 300
Study: 21813073

Group type: EXPERIMENTAL
Intervention: Risperidone treatment (2 to 6 mg/d) for 2 weeks
Number of subjects: 145

Group type: COMPARATOR
Intervention: Olanzapine treatment (10 to 20 mg/d) for 10 weeks (for nonresponders)
Number of subjects: 145
Study: 21122046

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment for 49 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hot wax treatment for 49 weeks
Number of subjects: 63
Study: 19034126

Group type: EXPERIMENTAL
Intervention: unpreserved 0.4% hyaluronic acid eye drops 150 mOsm/L
Number of subjects: 28

Group type: COMPARATOR
Intervention: unpreserved 0.4% hyaluronic acid eye drops 300 mOsm/L
Number of subjects: 28
Study: 16025230

Group type: EXPERIMENTAL
Intervention: Acute ACE-inhibitor treatment (< 9 hours after MI)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study: 14728070

Group type: EXPERIMENTAL
Intervention: trimetazidine MR 35 mg
Number of subjects: 223

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 223
Study: 11748790

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9420366

Group type: EXPERIMENTAL
Intervention: Forgiveness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 0
Study: 7971411

Group type: EXPERIMENTAL
Intervention: Selected-partner support
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Peer-partner support
Number of subjects: 175

Group type: COMPARATOR
Intervention: No support
Number of subjects: 175
Study: 3121795

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2647933

Group type: EXPERIMENTAL
Intervention: Increased oral cyclosporine dose for 7 to 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 40
Study: 31132967

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 502

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 502
Study: 29157293

Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/day for 48 hours before surgery, increased to 10 mg/day for the first 24 hours after surgery, continued for 3 months)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 172
Study: 25547037

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention (psychoeducation and interoceptive exposure)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Health information control condition
Number of subjects: 97
Study: 23955138

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (CTCX group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy only (CT group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 20869704

Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 523

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 523
Study: 19137265

Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day) for 3 months
Number of subjects: 30
Study: 17127704

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: combination of peginterferon alpha‐2a and lamivudine
Number of subjects: 518

Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 518
Study: 15185991

Group type: EXPERIMENTAL
Intervention: Functional training of dysphagia with oral care (once a week for 3 years)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral care (non-training group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Functional training of dysphagia with oral care
Number of subjects: 21
Study: 11520728

Group type: EXPERIMENTAL
Intervention: Helium-oxygen (HeO(2))
Number of subjects: 18
Study: 9778327

Group type: EXPERIMENTAL
Intervention: Duke treadmill score (DTS)
Number of subjects: 0
Study: 7930275

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Thrombus formation presence
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Thrombus formation absence
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Type of lesion
Number of subjects: 159
Study: 3060429

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison between Prazosin and Hydrochlorothiazide
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 102
Study: 31688648

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (90%-95% of HRpeak)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Supervised moderate continuous training (60%-70% of HRpeak)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Recommendation of regular exercise on their own
Number of subjects: 215
Study: 31112386

Group type: EXPERIMENTAL
Intervention: Budesonide-Formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation as needed)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Albuterol (100 μg, two inhalations as needed)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Budesonide (200 μg, one inhalation twice daily) plus as-needed albuterol
Number of subjects: 668
Study: 28859664

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sequential combination of aerobic exercise and cognitive training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 25463413

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Usual care plus exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2331
Study: 23458695

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 435
Study: 22019960

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (4%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo iontophoresis (normal saline)
Number of subjects: 14
Study: 18093246

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16940374

Group type: EXPERIMENTAL
Intervention: Radiotherapy plans submitted to the QA team of the START trial
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Wedge angle used in radiotherapy plans
Number of subjects: 1400
Study: 14870468

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (50 patients, no oxytocin)
Number of subjects: 90
Study: 10815835

Group type: EXPERIMENTAL
Intervention: Basic fuchsin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alizarin complexone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcein blue
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxytetracycline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Xylenol orange
Number of subjects: 10
Study: 8978226

Group type: EXPERIMENTAL
Intervention: Rehabilitation programmes comprising psychological therapy, counselling, relaxation training, and stress management training over seven weekly group outpatient sessions for patients and spouses.
Number of subjects: 2328

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 2328
Study: 1538611

Group type: EXPERIMENTAL
Intervention: Economic analyses included in RCTs
Number of subjects: 51

Group type: COMPARATOR
Intervention: Later dates of publication
Number of subjects: 51

Group type: COMPARATOR
Intervention: Presence of a statement of study perspective
Number of subjects: 51

Group type: COMPARATOR
Intervention: Economic completeness and quality of research scores
Number of subjects: 51

Group type: COMPARATOR
Intervention: Deficiencies in economic analyses
Number of subjects: 51
Study: 6422914

Group type: EXPERIMENTAL
Intervention: High-titer alpha-interferon (100 X 10(6) IU/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifluridine
Number of subjects: 0
Study: 31439102

Group type: EXPERIMENTAL
Intervention: Parent communication intervention plus in-vehicle event recorder feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-vehicle event recorder feedback only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 29451185

Group type: EXPERIMENTAL
Intervention: Early stoma closure
Number of subjects: 100
Study: 27692733

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1861
Study: 24731015

Group type: EXPERIMENTAL
Intervention: Exercise training and review of airway clearance therapy (ACT) for 8 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 22738022

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) active
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS) off
Number of subjects: 8
Study: 20644014

Group type: EXPERIMENTAL
Intervention: Gene score based on 2 PLTP single nucleotide polymorphisms
Number of subjects: 4658
Study: 18679598

Group type: EXPERIMENTAL
Intervention: Neiguan (P6) electroacupoint stimulation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo control group (placement of electrodes without electroacupoint stimulation)
Number of subjects: 96
Study: 15960694

Group type: EXPERIMENTAL
Intervention: Basic intervention: one-time e-mail reminder highlighting six HF-specific clinical recommendations
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Augmented intervention: initial e-mail reminder supplemented by provider prompts, patient education material, and clinical nurse specialist outreach
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 354
Study: 12091679

Group type: EXPERIMENTAL
Intervention: 125 mL of contrast material at 2.5 mL/sec
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 100 mL of contrast material at 2.0 mL/sec
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 90 mL of contrast material at 1.5 mL/sec
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 70 mL of contrast material at 1.0 mL/sec
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Routine examinations with 40 seconds and 45 seconds start delays
Number of subjects: 70
Study: 10069785

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) at 60% of peak VO2, initially 3 times a week for 8 weeks, then twice a week for 1 year
Number of subjects: 99

Group type: COMPARATOR
Intervention: No Exercise (Control group)
Number of subjects: 99
Study: 7560641

Group type: EXPERIMENTAL
Intervention: Neocate formula for 2 months followed by a 7-day double-blind placebo-controlled challenge with the previously best tolerated formula
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 18
Study: 2155531

Group type: EXPERIMENTAL
Intervention: Intralesional interferon alfa-2b
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 387497

Group type: EXPERIMENTAL
Intervention: Hydrocortisone alcoholic solution
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hydrocortisone-17-alpha-butyrate
Number of subjects: 55
Study: 31028547

Group type: EXPERIMENTAL
Intervention: 3D white-light imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of 3D and NBI
Number of subjects: 20

Group type: COMPARATOR
Intervention: NBI
Number of subjects: 20

Group type: COMPARATOR
Intervention: NIR-ICG
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2D white-light imaging
Number of subjects: 20
Study: 31443072

Group type: EXPERIMENTAL
Intervention: Unfavorable outcome after aSAH treatment
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: Between-center differences in outcomes
Number of subjects: 5972

Group type: COMPARATOR
Intervention: Between-country differences in outcomes
Number of subjects: 5972
Study: 28338977

Group type: EXPERIMENTAL
Intervention: 100 mg d-cycloserine (DCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (SZ-PLC)
Number of subjects: 45
Study: 26278911

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rEPO), high-dose, repetitive administration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24123224

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg CR
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg CR
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Isradipine 20 mg CR
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Isradipine (all dosages)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg daily
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 99
Study: 21126245

Group type: EXPERIMENTAL
Intervention: Interpersonal Synchrony
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non‐Interpersonal Synchrony
Number of subjects: 50
Study: 18928483

Group type: EXPERIMENTAL
Intervention: Intermittent Antegrade Warm Blood Cardioplegia (IAWBC) every 15 minutes
Number of subjects: 97

Group type: COMPARATOR
Intervention: Modified Intermittent Antegrade Warm Blood Cardioplegia (M-IAWBC) with magnesium sulfate every 25 minutes
Number of subjects: 97
Study: 16352396

Group type: EXPERIMENTAL
Intervention: Ala111Glu polymorphism of the glyoxalase I gene
Number of subjects: 450

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 450
Study: 12725766

Group type: EXPERIMENTAL
Intervention: PAF patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 15
Study: 10690444

Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 4933

Group type: EXPERIMENTAL
Intervention: Exercise programme component interventions
Number of subjects: 4933

Group type: EXPERIMENTAL
Intervention: Exercise programmes
Number of subjects: 4933
Study: 1564212

Group type: COMPARATOR
Intervention: Streptokinase with subcutaneous heparin
Number of subjects: 41600

Group type: EXPERIMENTAL
Intervention: Streptokinase with intravenous heparin
Number of subjects: 41600

Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue-type plasminogen activator (rt-PA) with intravenous heparin
Number of subjects: 41600

Group type: EXPERIMENTAL
Intervention: Combination of streptokinase, rt-PA and intravenous heparin
Number of subjects: 41600
Study: 6377076

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional injection treatment
Number of subjects: 70
Study: 31204383

Group type: EXPERIMENTAL
Intervention: Multiple small incisions and negative-pressure wound therapy (NPWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional comprehensive treatment with additional small incisions and NPWT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional comprehensive treatment
Number of subjects: 0
Study: 30522663

Group type: EXPERIMENTAL
Intervention: Low-dose drug-coated balloon (DCB)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty balloon (PTA)
Number of subjects: 294
Study: 25961604

Group type: EXPERIMENTAL
Intervention: Self-controlled task difficulty during early practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial self-control of task difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-control during early practice
Number of subjects: 0
Study: 24658598

Group type: EXPERIMENTAL
Intervention: Oral double-dose esomeprazole 40 mg twice daily (n=93)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Oral standard-dose esomeprazole 40 mg once daily (n=94)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (Rockall scores <6, n=89)
Number of subjects: 293
Study: 22508707

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 50
Study: 19766977

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment with usual obstetric care
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual obstetric care and sham ultrasound treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual obstetric care only
Number of subjects: 144
Study: 19061696

Group type: EXPERIMENTAL
Intervention: Remote monitoring using wireless telemetry
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard in-office care
Number of subjects: 2000
Study: 16260511

Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol (0.014 mg/d)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 11876692

Group type: EXPERIMENTAL
Intervention: rhIL‐11 15 microg/kg once weekly
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: rhIL‐11 7.5 microg/kg twice weekly
Number of subjects: 148
Study: 10206248

Group type: EXPERIMENTAL
Intervention: Intramedullary nail and wire towrope (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramedullary nail and external fixation device (Group B)
Number of subjects: 30
Study: 9592325

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lomefloxacin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fleroxacin (open trial)
Number of subjects: 110
Study: 1670631

Group type: EXPERIMENTAL
Intervention: 3.0 g oral sulfasalazine plus 20 mg twice daily rectal prednisolone enemas (group I, N = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 2.0 g twice daily rectal sucralfate enemas plus oral placebo (group II, N = 19)
Number of subjects: 37
Study: 6623019

Group type: EXPERIMENTAL
Intervention: Nonsteroid anti-inflammatory drugs (NSAIDs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Remission-inducing drugs (RIDs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clinical score
Number of subjects: 68

Group type: COMPARATOR
Intervention: Laboratory tests (erythrocyte sedimentation rate and serum C-reactive protein)
Number of subjects: 68
Study: 30411599

Group type: EXPERIMENTAL
Intervention: Sexual intercourse on the night before the tests
Number of subjects: 10

Group type: COMPARATOR
Intervention: No sexual intercourse on the five days prior to the tests (control condition)
Number of subjects: 10
Study: 28235887

Group type: EXPERIMENTAL
Intervention: Capsaicin administration to evoke coughs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methacholine administration to induce bronchoconstriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 26965791

Group type: EXPERIMENTAL
Intervention: Prednisolone 35 mg qd
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg qd
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg tid
Number of subjects: 113